Literature DB >> 2682592

Enhanced bioavailability of subcutaneously injected insulin coadministered with collagen in rats and humans.

R Hori1, F Komada, S Iwakawa, Y Seino, K Okumura.   

Abstract

The present study was undertaken to develop an agent that stabilizes insulin injected subcutaneously. 125I-Porcine insulin with 0.2 U/kg unlabeled porcine insulin was subcutaneously injected with or without collagen in the rat under the depilated skin of the back. At various times, the radioactivity in subcutaneous tissue was assayed for insulin and its metabolites by gel filtration. The degradation and absorption rate constants of insulin at the subcutaneous injection site were estimated according to a one-compartment model. The degradation rate constant of insulin in the presence of collagen at the injection site was less than half of the control rate. The inhibition was confirmed by increases in the immunoreactive insulin plasma levels and the hypoglycemic effect in rats and healthy volunteers. We postulate that collagen prevents insulin from being degraded by inhibiting proteolytic enzymes, mainly collagenase-like peptidase, in subcutaneous tissue.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2682592     DOI: 10.1023/a:1015987800808

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Collagen as a vehicle for drug delivery. Preliminary report.

Authors:  A L Rubin; K H Stenzel; T Miyata; M J White; M Dunn
Journal:  J Clin Pharmacol       Date:  1973 Aug-Sep       Impact factor: 3.126

2.  Collagen dialysis membranes: initial clinical evaluation.

Authors:  K H Stenzel; J F Sullivan; T Miyata; A L Rubin
Journal:  Trans Am Soc Artif Intern Organs       Date:  1969

3.  The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects.

Authors:  M Berger; H J Cüppers; P A Halban; R E Offord
Journal:  Diabetes       Date:  1980-01       Impact factor: 9.461

4.  Properties of "enkephalinase" from rat kidney: comparison of dipeptidyl-carboxypeptidase and endopeptidase activities.

Authors:  B Malfroy; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1982-05-31       Impact factor: 3.575

5.  Matched glucose responses to insulin administered subcutaneously and intravenously. Evidence for subcutaneous inactivation of insulin.

Authors:  R W Stevenson; T I Tsakok; J A Parsons
Journal:  Diabetologia       Date:  1980-05       Impact factor: 10.122

6.  Potentiation of the hypoglycemic effect of insulin by thiorphan, an enkephalinase inhibitor.

Authors:  R E Chipkin; W Kreutner; W Billard
Journal:  Eur J Pharmacol       Date:  1984-06-15       Impact factor: 4.432

7.  In vivo conversion of peptide drugs into high molecular weight forms.

Authors:  R Hori; Y Saito; M Yasuhara; K Okumura
Journal:  J Pharmacobiodyn       Date:  1984-12

8.  Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects.

Authors:  S M Guerra; A E Kitabchi
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

9.  Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.

Authors:  G Williams; J C Pickup; S Bowcock; E Cooke; H Keen
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

10.  The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients.

Authors:  T Kobayashi; S Sawano; T Itoh; K Kosaka; H Hirayama; Y Kasuya
Journal:  Diabetes       Date:  1983-04       Impact factor: 9.461

View more
  3 in total

1.  Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.

Authors:  K Okumura; Y Kiyohara; F Komada; S Iwakawa; M Hirai; T Fuwa
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

2.  Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors.

Authors:  M Takeyama; T Ishida; N Kokubu; F Komada; S Iwakawa; K Okumura; R Hori
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.